+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial



Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial



Lancet 378(9795): 983-990



Asthma exacerbations during pregnancy are common and can be associated with substantial maternal and fetal morbidity. Treatment decisions based on sputum eosinophil counts reduce exacerbations in non-pregnant women with asthma, but results with the fraction of exhaled nitric oxide (F(E)NO) to guide management are equivocal. We tested the hypothesis that a management algorithm for asthma in pregnancy based on F(E)NO and symptoms would reduce asthma exacerbations. We undertook a double-blind, parallel-group, controlled trial in two antenatal clinics in Australia. 220 pregnant, non-smoking women with asthma were randomly assigned, by a computer-generated random number list, before 22 weeks' gestation to treatment adjustment at monthly visits by an algorithm using clinical symptoms (control group) or F(E)NO concentrations (active intervention group) used to uptitrate (F(E)NO >29 ppb) or downtitrate (F(E)NO <16 ppb) inhaled corticosteroid dose. Participants, caregivers, and outcome assessors were masked to group assignment. Longacting β2 agonist and minimum dose inhaled corticosteroid were used to treat symptoms when F(E)NO was not increased. The primary outcome was total asthma exacerbations (moderate and severe). Analysis was by intention to treat. This study is registered with the Australian and New Zealand Clinical Trials Registry, number 12607000561482. 111 women were randomly assigned to the F(E)NO group (100 completed) and 109 to the control group (103 completed). The exacerbation rate was lower in the F(E)NO group than in the control group (0·288 vs 0·615 exacerbations per pregnancy; incidence rate ratio 0·496, 95% CI 0·325-0·755; p=0·001). The number needed to treat was 6. In the F(E)NO group, quality of life was improved (score on short form 12 mental summary was 56·9 [95% CI 50·2-59·3] in F(E)NO group vs 54·2 [46·1-57·6] in control group; p=0·037) and neonatal hospitalisations were reduced (eight [8%] vs 18 [17%]; p=0·046). Asthma exacerbations during pregnancy can be significantly reduced with a validated F(E)NO-based treatment algorithm. National Health and Medical Research Council of Australia.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036203172

Download citation: RISBibTeXText

PMID: 21907861

DOI: 10.1016/s0140-6736(11)60971-9


Related references

Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Yearbook of Pulmonary Disease 2012: 10-13, 2012

Management of Asthma in Pregnancy Guided by Measurement of Fraction of Exhaled Nitric Oxide. Obstetric Anesthesia Digest 32(3): 188-189, 2012

The Breathing for Life Trial: a randomised controlled trial of fractional exhaled nitric oxide (FENO)-based management of asthma during pregnancy and its impact on perinatal outcomes and infant and childhood respiratory health. Bmc Pregnancy and Childbirth 16: 111, 2016

Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology 49(7): 624-631, 2014

Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet 372(9643): 1065-1072, 2008

Management of Asthma Based on Exhaled Nitric Oxide in Addition to Guideline-Based Treatment for Inner-City Adolescents and Young Adults: A Randomised Controlled Trial. Pediatrics 124(Suppl.): S147-S147, 2009

Anti-inflammatory treatment of atopic asthma guided by exhaled nitric oxide: a randomized, controlled trial. Journal of Allergy and Clinical Immunology. in Practice 1(6): 639, 2015

Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid dose in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal 7(2): 204-213, 2013

The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine 176(3): 231-237, 2007

Dose-dependent reduction in exhaled nitric oxide in patients with asthma regularly treated with 100 mug or 400 mug budesonide in a double blind placebo-controlled parallel group study. European Respiratory Journal Suppl. 10(25): 295S, 1997

Randomised double-blind placebo-controlled study of the effect of inhibition of nitric oxide synthesis in bradykinin-induced asthma. Lancet (North American Edition) 348(9024): 374-377, 1996

Double blind randomised controlled trial of two different breathing techniques in the management of asthma. Thorax 61(8): 651-656, 2006

Exhaled nitric oxide fraction as an add-on to ACQ-7 for not well controlled asthma detection. Plos one 8(10): E77085, 2013

Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: A dual centre randomized controlled trial. Pediatric Pulmonology 50(6): 535-543, 2015

New method for single-breath fraction of exhaled nitric oxide measurement with improved feasibility in preschool children with asthma. Pediatric Allergy and Immunology 26(7): 662-667, 2015